Evidence map›Paper›PMID 35701724›Full record

ArticleInfection2022

Remdesivir-induced bradycardia in a 26-year-old patient with COVID-19: a case report.

Katarzyna Guziejko, Jaroslaw Talalaj, Monika Chorazy, Monika Groth, Anna Moniuszko-Malinowska

Open access · hybridAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Infection, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 50% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Katarzyna Guziejko2nd Department of Lung Diseases and Tuberculosis, Medical University of Bialystok, Zurawia 14, 15-540, Bialystok, Poland. kguziejko@wp.pl.ORCID http://orcid.org/0000-0002-2646-364X
Jaroslaw TalalajDepartment of Rehabilitation, Medical University of Bialystok, Bialystok, Poland.
Monika ChorazyDepartment of Neurology, Medical University of Bialystok, Bialystok, Poland.
Monika GrothDepartment of Infectious Diseases and Neuroinfections, Medical University of Bialystok, Bialystok, Poland.
Anna Moniuszko-MalinowskaDepartment of Infectious Diseases and Neuroinfections, Medical University of Bialystok, Bialystok, Poland.
Medical University of Białystok · PL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeRemdesivir is the first line hospital treatment of the SARS-CoV-2 infection. Despite its widespread use during COVID-19 pandemic, a limited number of data, also conflicting, are available about the frequency of cardiological side-effects. Additionally, identification of patients who belong to the risk groups for cardiovascular complications of antiviral treatment is difficult. CASE DESCRIPTION: Case description We present a case of a 26 year old patient, a soldier with COVID-19 and no comorbidities, who developed marked sinus bradycardia during remdesivir therapy. The bradycardia resolved few days after the end of antiviral treatment.

conclusionOur case emphasizes the key importance of the correct monitoring of patients receiving remdesivir, even those who do not have pre-existing heart conditions.

Indexed as

COVID-19 Drug TreatmentAdenosine MonophosphateAdultAlanineAntiviral AgentsBradycardiaHumansPandemicsSARS-CoV-2Adenosine MonophosphateAlanineAntiviral AgentsremdesivirBradycardiaCOVID-19ECGRemdesivirSARS-CoV-2

Identifiers

PMID35701724
PMCPMC9196856
OpenAlexW4282822183

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.